Japan’s Astellas Reaches Patent Agreement With Taiyo On Cefdinir
This article was originally published in PharmAsia News
Tokyo-based Astellas Pharma announced it has reached a settlement agreement with Nagoya-based Taiyo Yakuhin over antibiotic drug Cefzon (cefdinir). Taiyo manufactured and marketed generic products of cefdinir that violated Astellas's patent, according to the company. Taiyo agreed to pay an undisclosed settlement amount to Astellas. (Click here for more - Japanese language
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.